This inventor holds 2 USPTO granted patents. Top assignees: Jcr Pharmaceuticals Co., Ltd., New York Blood Center, Inc., Santen Pharmaceutical Co., Ltd.. Active years: 1994-1996.
Company Filing History:
2 out of 80 
2 out of 194 
2 out of 282 
Years Active: 1994-1996
Title: The Innovative Contributions of Adrianne J Setton
Introduction
Adrianne J Setton is a notable inventor based in New York, NY (US). She has made significant contributions to the field of ophthalmology through her innovative inventions. With a total of 2 patents, her work focuses on developing solutions that enhance the treatment of ophthalmic wounds.
Latest Patents
One of her latest patents is a fibronectin-containing ophthalmic solution, which is a stable and soluble multi-dose formulation. This solution comprises fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. The patent also details a method for treating ophthalmic wounds using this solution. Additionally, it includes a process for preparing fibronectin for ophthalmic use, a method for lyophilizing an aqueous solution of fibronectin free of albumin, and a technique for inhibiting bacterial growth in the ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin. Furthermore, it describes a method for administering a wound-healing accelerator solution for the treatment of ophthalmic wounds.
Career Highlights
Adrianne has worked with reputable organizations such as the New York Blood Center, Inc. and JCR Pharmaceuticals Co., Ltd. Her experience in these institutions has contributed to her expertise in the field of ophthalmology and innovation.
Collaborations
Throughout her career, Adrianne has collaborated with esteemed colleagues, including Toyohiko Nishimura and Bernard Horowitz. These collaborations have likely enriched her research and development efforts.
Conclusion
Adrianne J Setton's contributions to ophthalmology through her patents and career achievements highlight her role as an influential inventor. Her innovative solutions continue to pave the way for advancements in the treatment of ophthalmic conditions.